The Dana-Farber Cancer Institute trial (NCT04030507) will contain four patient cohorts: patients with triple-negative breast cancer will undergo screening MRI of the brain (single arm, one cohort), patients with ER+/HER2– and HER2+ subtypes will be randomised between screening MRI of the brain or not (two cohorts) and patients with inflammatory BC will undergo screening MRI of the brain (one cohort). The gene discussed is ERBB2; the disease is triple-negative breast carcinoma.